Novel therapeutic approaches for steroid-resistant nephrotic syndrome in paediatric patients: a comprehensive review

Authors

  • Rajan Kumar Department of Pediatrics, All India Institute of Medical Sciences, Deoghar, Jharkhand, India
  • Santosh Kumar Department of Pediatrics, Maulana Azad Medical College, Delhi, India
  • Deepak Kumar Department of PMR, All India Institute of Medical Sciences, Deoghar, Jharkhand, India
  • Ehtesham Ansari Department of Pediatrics, All India Institute of Medical Sciences, Deoghar, Jharkhand, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20241384

Keywords:

SRNS, Extracorporeal therapy, Galactose, ACTH

Abstract

Steroid-resistant nephrotic syndrome poses a significant therapeutic challenge in paediatric nephrology. Previously exact cause of steroid-resistant nephrotic syndrome was mostly unknown. Recently, advancements in diagnostic intervention, they are found to be a heterogeneous entity having an immune basis and genetic aetiology. With a better understanding of the pathogenesis of SRNS, leading to the development of novel therapeutic strategies. Novel therapeutic options include extracorporeal therapy, monoclonal antibodies, stem cell therapy, ACTH and galactose. The aim of this study was to provide an overview of emerging therapies for SRNS in paediatric populations.

References

Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. The Lancet. 2018;392(10141):61-74.

Lee JM, Kronbichler A, Shin JI, Oh J. Current understandings in treating children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2021;36(4):747-61.

Nourbakhsh N, Mak RH. Steroid-resistant nephrotic syndrome: past and current perspectives. Pediatric Health Med Ther. 2017;8:29-37.

Angeletti A, Bruschi M, Kajana X, La Porta E, Spinelli S, Caridi G, et al. Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment. Front Immunol. 2023;14:1213203.

Bierzynska A, McCarthy HJ, Soderquest K, Sen ES, Colby E, Ding WY, et al. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. Kidney Int. 2017;91(4):937-47.

Au E, Campbell KN. Extracorporeal Therapy for Idiopathic Nephrotic Syndrome. Kidney Int Rep. 2021;6(8):2019-21.

Kronbichler A, Gauckler P, Lee KH, Shin JI, Malvezzi P, Mayer G. Immunoadsorption in nephrotic syndrome: Where are we now and where are we going from here? Atheroscler Suppl. 2019;40:55-60.

Raina R, Wang J, Sharma A, Chakraborty R. Extracorporeal Therapies in the Treatment of Focal Segmental Glomerulosclerosis. Blood Purif. 2020;49(5):513-23.

Dall'Amico R, Ghiggeri G, Carraro M, Artero M, Ghio L, Zamorani E, et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis. 1999;34(6):1048-55.

Biesenbach P, Schmaldienst S, Smolen JS, Hörl WH, Derfler K, Stummvoll GH. Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity. Atheroscler Suppl. 2009;10(5):114-21.

Kobayashi S. Applications of LDL-apheresis in nephrology. Clin Exp Nephrol. 2008;12(1):9-15.

Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1975;1(7918):1208-11.

Bosch T, Lennertz A, Schmidt B, Fink E, Keller C, Toepfer M, et al. DALI apheresis in hyperlipidemic patients: biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood. Artif Organs. 2000;24(2):81-90.

Muso E. Beneficial effect of LDL-apheresis in refractory nephrotic syndrome. Clin Exp Nephrol. 2014;18(2):286-90.

Dogra S, Kaskel F. Steroid-resistant nephrotic syndrome: a persistent challenge for pediatric nephrology. Pediatr Nephrol. 2017;32(6):965-74.

Wang CS, Travers C, McCracken C, Leong T, Gbadegesin R, Quiroga A, et al. Adrenocorticotropic Hormone for Childhood Nephrotic Syndrome: The ATLANTIS Randomized Trial. Clin J Am Soc Nephrol. 2018;13(12):1859-65.

Chakraborty R, Mehta A, Nair N, Nemer L, Jain R, Joshi H, et al. ACTH Treatment for Management of Nephrotic Syndrome: A Systematic Review and Reappraisal. Int J Nephrol. 2020;2020:2597079.

Wang Y, Dang X, Wu X, Li Y, He Q, Li X. Real-word adrenocorticotropic hormone treatment for childhood-onset nephrotic syndrome. Front Pediatr. 2023;11:1044075.

Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol. 2009;37(12):1445-53.

Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838-43.

Morello W, Budelli S, Bernstein DA, Montemurro T, Montelatici E, Lavazza C, et al. First clinical application of cord blood mesenchymal stromal cells in children with multi-drug resistant nephrotic syndrome. Stem Cell Res Ther. 2022;13(1):420.

Mishra OP, Singh AK, Pohl M, Kumar B, Batra VV, Narayan G. Oral galactose in children with focal and segmental glomerulosclerosis: a novel adjunct therapy. Clin Kidney J. 2014;7(1):83-5.

Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, et al. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. BMC Nephrol. 2015;16:111.

Ortiz A, Bustos C, Alonso J, Alcázar R, López-Armada MJ, Plaza JJ, et al. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. Adv Nephrol Necker Hosp. 1995;24:53-77.

Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, et al. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010;55(1):50-60.

Jayaraman VK, Thomas M. Abatacept experience in steroid and rituximab-resistant focal segmental glomerulosclerosis. BMJ Case Rep. 2016;2016:bcr2016214396.

Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013;369(25):2416-23.

Downloads

Published

2024-05-27

Issue

Section

Review Articles